HL
CRL icon

HeadInvest LLC’s Charles River Laboratories CRL Stock Holding History

HeadInvest LLC’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$774 – 319
2023
Q3 		$774 Buy
+4
New +$821 ﹤0.01% 717

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

HeadInvest LLC's CRL Position: Q4 2023 in Review

HeadInvest LLC sold out of Charles River Laboratories (CRL) in Q4 2023, closing a stake of 4 shares — an estimated $774 sold.

HeadInvest LLC first reported a position in CRL in Q3 2023 and held it in 1 quarter. The position peaked at $774 in Q3 2023. 634 funds tracked by Wall St. Rank hold CRL as of Q4 2023.

  • HeadInvest LLC reported no remaining Charles River Laboratories position as of Q4 2023 after selling out during the quarter.
  • HeadInvest LLC sold 4 Charles River Laboratories shares in Q4 2023, an estimated $774.
  • HeadInvest LLC first reported a position in Charles River Laboratories in Q3 2023 and held it in 1 quarter.
  • HeadInvest LLC's Charles River Laboratories position peaked at $774 in Q3 2023.
  • 634 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.